Details for Patent: 8,357,393

Title:	Transdermal delivery rate control using amorphous pharmaceutical compositions
Abstract:	A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (C.sub.max) to the average concentration (C.sub.avg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
Inventor(s):	Morgan; Timothy Matthias (Victoria, AU), Wilkins; Nina Frances (Victoria, AU), Klose; Kathryn Taci-Jane (Victoria, AU), Finnin; Barrie Charles (Victoria, AU), Reed; Barry Leonard (Victoria, AU)
Assignee:	Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Filing Date:	Dec 07, 2004
Application Number:	11/004,926
Claims:	1. A non-occlusive transdermal pharmaceutical composition suitable for transdermal administration and capable of transdermal delivery of a physiologically active agent comprising: (a) from 0.1% to 10% by weight of one or more active agents selected from the group consisting of fentanyl, buspirone and granisetron; (b) from 0.1% to 10% by weight of one or more dermal penetration enhancers selected from the group consisting of octyl salicylate and Padimate O; and (c) from 85% to 99.8% by weight of a volatile solvent selected from the group consisting of ethanol, isopropanol, and mixtures thereof; wherein the combination of physiologically active agent(s) and dermal penetration enhancer(s) is such that the composition, upon application and evaporation of the solvent at physiological temperatures, forms an amorphous deposit comprising an amorphous phase, containing the dermal penetration enhancer(s) and physiologically active agent(s), which amorphous phase does not display crystallinity, when determined in vitro by Brightfield microscopy after evaporation of the solvent at 32.degree. C. and ambient relative humidity for 24 hours. 2. A composition according to claim 1, wherein the active agent is fentanyl. 3. A composition according to claim 2, wherein the molar ratio of active agent to dermal penetration enhancer is from 1:20 to 20:1. 4. A composition according to claim 1, wherein the composition consists of the physiologically active agent(s), the penetration enhancer(s), the volatile solvent(s) and, optionally, a gelling agent. 5. A composition according to claim 1, wherein the penetration enhancer is present in an amount in the range of from 5% to 10% by weight of the composition. 6. A composition according to claim 5, wherein the active agent is fentanyl. 7. A composition according to claim 1, wherein the penetration enhancer is octyl salicylate. 8. A composition according to claim 1, wherein the composition is contained in a chamber of a spray applicator device comprising a valve for delivering the composition from the chamber, and a nozzle for dispensing the composition, wherein the spray applicator device provides a metered dose from the nozzle. 9. A non-occlusive transdermal pharmaceutical composition suitable for transdermal administration and capable of transdermal delivery of a physiologically active agent comprising: (a) from 0.1% to 10% by weight of the physiologically active agent fentanyl; (b) from 0.1% to 10% by weight of the dermal penetration enhancer octyl salicylate; and (c) from 85% to 99.8% by weight of a volatile solvent selected from the group consisting of ethanol, isopropanol, and mixtures thereof; wherein the combination of physiologically active agent and dermal penetration enhancer is such that the composition, upon application and evaporation of the solvent at physiological temperatures, forms an amorphous deposit comprising an amorphous phase, containing the dermal penetration enhancer(s) and physiologically active agent(s), which amorphous phase does not display crystallinity, when determined in vitro by Brightfield microscopy after evaporation of the solvent at 32.degree. C. and ambient relative humidity for 24 hours. 10. A composition according to claim 9, wherein the composition is free of gelling agent.